Targeting Src and Epidermal Growth Factor Receptor in Colorectal Cancer: Rationale and Progress Into the Clinic

Por Kopetz, Scott
Publicado em 2007

Commentary: Practice Patterns and Potential Impact on Quality Measures for a Practicing Physician

Por Eng, Cathy, Kopetz, Scott
Publicado em 2009

The Src Family of Protein Tyrosine Kinases: A New and Promising Target for Colorectal Cancer Therapy

Por Lieu, Christopher, Kopetz, Scott
Publicado em 2010

BRAF inhibitors in clinical oncology

Por Morris, Van, Kopetz, Scott
Publicado em 2013

Challenges and strategies for identifying biomarkers for colorectal cancer

Por Conte, Bruno, Kopetz, Scott
Publicado no Colorectal Cancer (2013)

Novel Therapies in Development for Metastatic Colorectal Cancer

Por Lee, Michael S., Kopetz, Scott
Publicado no Gastrointest Cancer Res (2014)

Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology

Por Katsiampoura, Anastasia, Kopetz, Scott
Publicado no Gastrointest Cancer Res (2014)

BRAF-directed Therapy in Metastatic Colorectal Cancer

Por Korphaisarn, Krittiya, Kopetz, Scott
Publicado no Cancer J (2016)

Tumor Microenvironment in Gene Signatures: Critical Biology or Confounding Noise?

Por Morris, Jeffrey S., Kopetz, Scott
Publicado no Clin Cancer Res (2016)

The Promise of Patient-Derived Xenografts: The best laid plans of mice and men

Por Kopetz, Scott, Lemos, Robert, Powis, Garth
Publicado em 2012

Addition of RAS Mutation Status May Strengthen the Predictive Model for Progression of Indeterminate Pulmonary Nodules

Por Mise, Yoshihiro, Kopetz, Scott, Vauthey, Jean-Nicolas
Publicado no Ann Surg (2016)

Expanded RAS: Refining the Patient Population

Por Atreya, Chloe E., Corcoran, Ryan B., Kopetz, Scott
Publicado no J Clin Oncol (2015)

Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie

Por Loree, Jonathan M., Kopetz, Scott, Raghav, Kanwal P. S.
Publicado no J Gastrointest Oncol (2017)

Topoisomerase IIα in Chromosome Instability and Personalized Cancer Therapy

Por Chen, Tao, Sun, Yan, Ji, Ping, Kopetz, Scott, Zhang, Wei
Publicado no Oncogene (2014)

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy

Por Li Kuiyuan, Ma Ying, Kumar Vikas, Chang David Z, Kopetz Scott
Publicado em 2009-04-01

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy

Por Chang, David Z, Kumar, Vikas, Ma, Ying, Li, Kuiyuan, Kopetz, Scott
Publicado em 2009

Systemic cytotoxic and biologic therapies for colorectal cancer liver metastases: expert consensus statement

Por Clary, Bryan M, Grothey, Axel, Kopetz, Scott, Marsh, Robert D W
Publicado em 2013

Early-Onset Signet-Ring Cell Adenocarcinoma of the Colon: A Case Report and Review of the Literature

Por Khan, Maliha, Korphaisarn, Krittiya, Saif, Aneeqa, Foo, Wai C., Kopetz, Scott
Publicado no Case Rep Oncol Med (2017)

Cancer in silico Drug Discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes

Por Lucas, F. Anthony San, Fowler, Jerry, Chang, Kyle, Kopetz, Scott, Vilar, Eduardo, Scheet, Paul
Publicado no Mol Cancer Ther (2014)

Convergence of Nanotechnology and Cancer Prevention: Are We There Yet?

Por Menter, David G., Patterson, Sherri L., Logsdon, Craig D., Kopetz, Scott, Sood, Anil K., Hawk, Ernest T.
Publicado no Cancer Prev Res (Phila) (2014)